Fig. 2
From: LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus
BL001 decreases insulitis and modulates the blood cytokine profile. Histology (representative images, scale bar: 25 µM) and morphometry at a, b 4 and c, d 8 weeks revealed that treatment with 10 mg/kg b.w. BL001 decreased the incidence and severity of insulitis in immunized RIP-B7.1 mice. At 8 weeks, BL001-treated and immunized mice that developed hypeglycemia exhibited a similar degree of insulitis to the BL001-treated and immunized mice that were normoglycemic at 4 weeks. Impact of BL001 treatment on the profile of cytokines, chemokines and TGFbeta at 4 weeks (e, g, i) and 8 weeks (f, h, j). Plots show individual mice values. *p < 0.05, **p < 0.01, and ***p < 0.001, one-way ANOVA
